Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

In this trial involving more than 24,000 participants, the efficacy of two doses of a viruslike-particle, plant-based vaccine with adjuvant was 69.5% against symptomatic Covid-19 and 78.8% against moderate-to-severe disease. More than 80% of vaccine recipients had local or systemic adverse effects,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2022-06, Vol.386 (22), p.2084-2096
Hauptverfasser: Hager, Karen J., Pérez Marc, Gonzalo, Gobeil, Philipe, Diaz, Ricardo S., Heizer, Gretchen, Llapur, Conrado, Makarkov, Alexander I., Vasconcellos, Eduardo, Pillet, Stéphane, Riera, Fernando, Saxena, Pooja, Geller Wolff, Priscila, Bhutada, Kapil, Wallace, Garry, Aazami, Hessam, Jones, Christine E., Polack, Fernando P., Ferrara, Luciana, Atkins, Judith, Boulay, Iohann, Dhaliwall, Jiwanjeet, Charland, Nathalie, Couture, Manon M.J., Jiang-Wright, Julia, Landry, Nathalie, Lapointe, Sophie, Lorin, Aurélien, Mahmood, Asif, Moulton, Lawrence H., Pahmer, Emmy, Parent, Julie, Séguin, Annie, Tran, Luan, Breuer, Thomas, Ceregido, Maria-Angeles, Koutsoukos, Marguerite, Roman, François, Namba, Junya, D’Aoust, Marc-André, Trepanier, Sonia, Kimura, Yosuke, Ward, Brian J.
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvants
Adverse events
Antibodies
Coronavirus
Coronaviruses
COVID-19 vaccines
Glycoproteins
Infectious Disease
Laboratories
Original
Pandemics
Placebos
Population
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Statistical analysis
Vaccine efficacy
Vaccines
Viral Infections
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this trial involving more than 24,000 participants, the efficacy of two doses of a viruslike-particle, plant-based vaccine with adjuvant was 69.5% against symptomatic Covid-19 and 78.8% against moderate-to-severe disease. More than 80% of vaccine recipients had local or systemic adverse effects, which were generally mild and short-lived.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2201300